2015

Aktas O. Ein Paradigmenwechsel und die Zukunft. In: Berger T, Linnebank M, Wiendl H (eds.) Betaferon ® 2013, 25 Jahre Multiple Sklerose Forschung. Springer 2015, in press.

Albrecht P, Blasberg C, Lukas S, Ringelstein M, Müller AK, Harmel J, Kadas EM, Finis D, Guthoff R, Aktas O, Hartung HP, Paul F, Brandt AU, Berlit P, Methner A, Kraemer M. Retinal pathology in idiopathic moyamoya angiopathy detected by optical coherence tomography.Neurology 2015; 85: 521-527.

Alkemade A, Schnitzler A, Forstmann BU. Topographic organization of the human and non-human primate subthalamic nucleus. Brain Structure & Function 2015; 220: 3075-3086.

Arendt G. Die HIV-assoziierte Demenz (HAD) in der Ära moderner antiretroviraler Kombinationstherapien (cART). Brandt, Diener, Gerloff (eds.) Der Neurologe & Psychiater2015, in press.

Arendt G, Nolting T. Neuropsychiatric side effects of efavirenz therapy. Journal of Neurobehavioral HIV Medicine 2015, in press.

Arendt G, Maschke M. HIV-Infektion und AIDS: neurologische Manifestationen. In: Brandt, Diener, Gerloff (eds.) Therapie und Verlauf neurologischer Erkrankungen. Kohlhammer Verlag, 6. Aufl., 2015, in press.

Arendt G. Idiopathische intrakranielle Hypertension: Pathogenese, Symptome, Diagnostik und Therapie - ein Update. Der Ophthalmologe 2015, in press.

Arima H, Heeley E, Delcourt C, Hirakawa Y, Wang X, Woodward M, Robinson T, Stapf C, Parsons M, Lavados PM, Huang Y, Wang J, Chalmers J, Anderson CS; INTERACT2 Investigators; INTERACT2 Investigators [Jander S]. Optimal achieved blood pressure in acute intracerebral hemorrhage: INTERACT2. Neurology 2015; 84: 464-471.

Baumgarten TJ, Schnitzler A, Lange J. Beta oscillations define discrete perceptual cycles in the somatosensory domain. Proceedings of the National Academy of Sciences of the United States of America 2015, in press.

Bayry J, Hartung HP, Kaveri SV. IVIg for relapsing-remitting multiple sclerosis: promises and uncertainties. Trends in Pharmacological Sciences 2015; 36: 419-421.

Berndt C, Lillig CH. Redox regulation of differentiation and de-differentiation. Biochimica et Biophysica Acta 2015; 1850: 1467-1468.

Beste C, Mückschel M, Elben S, Hartmann JC, McIntyre CC, Saft C, Vesper J, Schnitzler A, Wojtecki L. Behavioral and neurophysiological evidence for the enhancement of cognitive control under dorsal pallidal deeps brain stimulation in Huntington's disease. Brain Structure & Function 2015, in press.

Brazda N, Estrada V, Voss C, Seide K, Trieu K, Müller HW. Experimental strategies to bridge large tissue gaps in the injured spinal cord after acute and chronic lesion. JoVE 2015, in press.

Brenner M, Butz M, May ES, Kahlbrock N, Kircheis G, Häussinger D, Schnitzler A. Patients with manifest hepatic encephalopathy can reveal impaired thermal perception. Acta Neurologica Scandinavica 2015; 132: 156-163.

Challagundla M, Koch JC, Ribas VT, Michel U, Kügler S, Ostendorf T, Bradke F, Müller HW, Bähr M, Lingor P. AAV-mediated expression of BAG1 and ROCK2-shRNA promote neuronal survival and axonal sprouting in a rat model of rubrospinal tract injury. Journal of Neurochemistry 2015; 134: 261-275.

Chin RL, Deng C, Bril V, Hartung HP, Merkies IS, Donofrio PD, van Doorn PA, Dalakas MC, Latov N. Follow-up nerve conduction studies in CIDP after treatment with IGIV-C: Comparison of patients with and without subsequent relapse. Muscle & Nerve 2015; 52: 498-502.

Cohen JA, Khatri B, Barkhof C, Comi G, Hartung HP, Montalban X, Pelletier J, Stites T, Ritter S, von Rosenstiel P, Tomic D, Kappos L; TRANSFORMS (TRial Assessing injectable interferoN vS. FTY720 Oral in RRMS) Study Group. Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. Journal of Neurology, Neurosurgery & Psychiatry 2015, in press.

Derfuss T, Curtin F, Guebelin C, Bridel C, Rasenack M, Matthey A, Pasquier RD, Schluep M, Desmeules J, Lang AB, Perron H, Faucard R, Porchet H, Hartung HP, Kappos L, Lalive PH. A phase IIa randomised clinical study of GNbAC1, a humanised monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus in multiple sclerosis patients. Multiple Sclerosis 2015; 285: 68-70.

Diekmann H, Kalbhen P, Fischer D. Characterization of optic nerve regeneration using transgenic zebrafish. Frontiers in Cellular Neuroscience 2015; 9: 118.

Diekmann H, Kalbhen P, Fischer D. Active mechanistic target of rapamycin plays an ancillary rather than essential role in zebrafish CNS axon regenration. Frontiers in Cellular Neuroscience 2015; 9: 251.

Diekmann H, Fischer D. Role of GSK3 in peripheral nerve regeneration. Neural Regeneration Research 2015, in press.

Dinkelbach L, Müller J, Poewe W, Delazer M, Elben S, Wolters A, Karner E, Wittstock M, Bennecke R, Schnitzler A, Volkmann J, Südmeyer M. Cognitive outcome of pallidal deep brain stimulation for primary cervical dystonia: one year follow up results of a prospective multicenter trial. Parkinsonism and Related Disorders 2015; 21: 976-80.

Dinkelbach L, Hartmann CJ, Mathys C, Wojtecki L, Hänggi D, Südmeyer M. Cervical dystonia caused by focal putaminal ischemia. Annals of Clinical and Translational Neurology 2015, in press.

Droby A, Panagoulias M, Albrecht P, Reuter E, Duning T, Hildebrandt A, Wiendl H, Zipp F, Methner A. A novel automated segmentation method for retinal layers in OCT images proves retinal degeneration after optic neuritis. The British Journal of Ophthalmology 2015, in press.

Dubey D, Kieseier BC, Hartung HP, Hemmer B, Miller-Little WA, Stuve O. Clinical management of multiple sclerosis and neuromyelitis optica with therapeutic monoclonal antibodies: approved therapies and emerging candidates. Expert Review of Clinical Immunology 2015; 11: 93-108.

Dubey D, Kieseier BC, Hartung HP, Hemmer B, Warnke C, Menge T, Miller-Little WA, Stuve O. Dimethyl fumarate in relapsing-remitting multiple sclerosis: rationale, mechanisms of action, pharmacokinetics, efficacy and safety. Expert Review of Neurotherapeutics 2015; 15: 339-346.

Fazekas F, Enzinger C, Schmidt R, Grittner U, Giese AK, Hennerici MG, Huber R, Jungehulsing GJ, Kaps M, Kessler C, Martus P, Putaala J, Ropele S, Tanislav C, Tatlisumak T, Thijs V, von Sarnowski B, Norrving B, Rolfs A; SIFAP 1 Investigators [Hartung HP]. Brain magnetic resonance imaging findings fail to suspect Fabry disease in young patients with an acute cerebrovascular event. Stroke 2015; 46:1548-1553.

Ferrea S, Saleh A, Wojtecki L, Schnitzler A, Südmeyer M. Diabetic hemichorea-hemiballism - Case report of a patient with endurig striatal lesion. Basal Ganglia 2015, in press.

Fischer D, Klaus A, Ray DE. Toxikologie des Nervensystems. In: Marquardt H, Schäfer S, Barth H (eds.) Toxikologie. 3. Aufl., Wissenschaftliche Verlagsgesellschaft Stuttgart, 2015, in press.

Fleischer W, Theiss S, Slotta J, Holland C, Schnitzler A. High-frequency voltage oscillations in cultured astrocytes. Physiological Reports 2015, in press.

Franzen D, Mathys C, Vesper J, Malzkorn B, Bohlen H, Seitz RJ. Progressive multifokale Leukenzephalopathie. Schwerwiegende Komplikation einer Immunsuppression. Deutsche Medizinische Wochenschrift 2015; 140: 1291-1293.

Gellert M, HanschmannEM, Lepka K, Berndt C, Lillig CH. Redox regulation of cytoskeletal dynamics during differentiation and de-differentiation. Biochimica et Biophysica Acta 2015; 1850: 1575-1587.

Gibbs E, Karim ME, Oger J; Steering Committee of the BENEFIT study. Antibody dissociation rates are predictive of neutralizing antibody (Nab) course: a comparison of interferon beta-1b-treated Multiple Sclerosis (MS) patients with transient versus sustained Nabs. Clinical Immunology 2015; 157: 91-101.

Gliem M, Krammes K, Liaw L, van Rooijen N, Hartung HP, Jander S. Macrophage-derived osteopontin induces reactive astrocyte polarization and promotes re-establishment of the blood brain barrier after ischemic stroke. Glia 2015, in press.

Gliem M, Klotz L, van Rooijen N, Hartung HP, Jander S. Hyperglycemia and PPARg antagonistically influence macrophage polarization and infarct healing after ischemic stroke.Stroke 2015; 46: 2935-2942.

Göttle P, Sabo JK, Heinen A, Venables G, Torres K, Tzekova N, Parras C, Kremer D, Hartung HP, Cate HS, Küry P. Oligodendroglial maturation is dependent on intracellular protein shuttling. Journal of Neuroscience 2015; 35: 906-919.

Gross J, Kujala J, Salmelin R, Schnitzler A. Non-invasive functional tomographic connectivity analysis with magnetoencephalography. In: Kringelbach M, Hansen P, Salmelin R (eds.)Magnetoencephalography. An introduction to methods. Oxford University Press, Oxford, 2015 in press.

Grützke B, Hucke S, Herold M, Posevitz-Fejfar A, Wildemann B, Kieseier BC, Dehmel T, Wiendl H, Klotrz L. Fingolimod promotes regulatory phenotype and function of B cells . Annals of Clinical and Translational Neurology 2015; 2: 119-130.

Haas J, Schwarz A, Korporal-Kunke M, Jarius S, Wiendl H, Kieseier BC, Wildemann B. Fingolimod does not impair T-cell release from the thymus and beneficially affects Treg function in patients with multiple sclerosis. Multiple Sclerosis 2015, in press.

Hartmann CJ, Klistorner AI, Brandt AU, Schroeder K, Kolbe R, Cohn E, Goebels N, Guthoff R, Aktas O, Hartung HP, Albrecht P. Axonal damage in papilledema linked to idiopathic intracranial hypertension as revealed by multifocal visual evoked potentials. Clinical Neurophysiology 2015; 126: 2040-2041.

Hartmann CJ, Wojtecki L, Vesper J, Volkmann J, Groiss SJ, Schnitzler A, Südmeyer M. Long-term evaluation of impedance levels and clinical development in subthalamic deep brain stimulation for Parkinson´s disease. Parkinsonism and Related Disorders 2015; 21: 1247-1250.

Hartung HP, Aktas O, Boyko AN. Alemtuzumab: A new therapy for active relapsing-remitting multiple sclerosis. Multiple Sclerosis 2015; 21: 22-34.

Hartung HP, Matthews V, Ross AP, Pitschnau-Michel D, Thalheim C, Ward-Abel N; on behalf of the Multiple Sclerosis-Nurse Empowering Education (MS-NEED) Study Group. Disparities in nursing of multiple sclerosis patients - results of a European nurse survey. Multiple Sclerosis 2015, in press.

Hartung H-P, Gold R. Mensch im Blick, Gehirn im Fokus. Nervenarzt 2015; 86: 923-924.

Hartung HP, Kappos L, Goodin DS, O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Jeffery D, Petkau J, White R, Bogumil T, Beckmann K, Stemper B, Suarez G, Sandbrink R, Pohl C. Predictors of disease activity in 857 patients with MS treated with interferon beta-1b.Journal of Neurology 2015, in press.

Hartung HP, Kieseier BC. (2015) Polyneuropathien, Immunneuropathien und hereditäre Neuropathien. In: Hacke W (ed.). Neurologie . 14. Aufl. Springer. Heidelberg. 783-811.

Heckel M, Kieseier BC, Schaper J, Mayatepek E, Rosenbaum T. Mitoxantrone as rescue therapy in two children with worsening multiple sclerosis. Journal of Pediatric Neurology2015, in press.

Hefter H. Inzidenz und Prävalenz neutralisierender AK in der Langzeit-Behandlung zervikaler Dystonien mit Botulinumtoxin. Thieme-Verlag, Stuttgart. 2015, in press.

Heinen A, Beyer F, Tzekova N, Hartung HP, Küry P. Fingolimod induces the transition to a nerve regeneration promoting Schwann cell phenotype. Experimental Neurology 2015; 271: 25-35.

Hildebrandt T, Knuesting J, Berndt C, Morgan B, Scheibe R. Cytosolic thiol switches regulating basic cellular functions: GAPDH as an information hub? Biological Chemistry2015; 396: 523-537.

Hohlbaum K, Wellner B, Dressel K, Lange I, Etcheverry L, Schulte S, Minneropp M, Südmeyer M, Huber W, Grande M, Amunts K, Grodzinsky Y, Heim S. Nachsprechen von Sätzen bei PPA-L. Sprache Stimme Gehör 2015; 39: 7-8.

Hohlfeld T, Weber AA, Junghans U, Schumacher M, Schrör K, Siebler M. Aspirin "type I-III resistance" in patients with acute ischemic stroke. Stroke 2015, in press.

Imöhl M, Möller J, Reinert RR, Perniciaro S, van der Linden M, Aktas O. Pneumococcal meningitis and vaccine effects in the era of conjugate vaccination: results of 20 years of nationwide surveillance in Germany. BMC Infectious Diseases 2015; 15: 61.

Ingwersen J, Menge T, Wingerath B, Kaya D, Graf J, Prozorovski T, Keller A, Backes C, Beier M, Scheffler M, Dehmel T, Kieseier BC, Hartung HP, Küry P, Aktas O. Natalizumab restores aberrant miRNA expression profile in multiple sclerosis and reveals a critical role for miR-20b.Annals of Clinical and Translational Neurology 2015; 2: 43-55.

Jarius S, Aktas O, Wildemann B. Gamma-aminobutyric acid receptor agonists, aquaporin-4, and neuromyelitis optica: a potential link. Medical Hypotheses 2015, in press.

Kappos L, Radue EM, Comi G, Montalban X, Butzkueven H, Wiendl H, Giovannoni G, Hartung HP, Derfuss T, Naegelin Y, Sprenger T, Mueller-Lenke N, Griffiths S, von Rosenstiel P, Gottschalk R, Zhang Y, Dahlke F, Tomic D; TOFINGO study group. Switing from natalizumab to fingolimod: a randomized, placebo-controlled study in RRMS. Neurology2015; 85: 29-39.

Kaufman M, Cree BA, De Sèze J, Fox RJ, Gold R, Hartung HP, Jeffery D, Kappos L, Montalbán X, Weinstock-Guttman B, Ticho B, Duda P, Pace A, Campagnolo D. Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE.Journal of Neurology 2015; 262: 326-336.

Kieseier BC, Wiendl H. Schädigungsmechanismen bei Multipler Sklerose. In: Zettl U, Mix E (eds.) Multiple Sklerose. Springer, Berlin, 2015, in press.

Kieseier BC. Entzündungsmediatoren als biologische Marker - Zytokine, Chemokine, Adhäsionsmoleküle und Metalloproteasen. In: Berger T (ed.) Biologische Marker für Diagnostik, Prognose und Therapie bei MS. Uni-Med Verlag, Bremen, 2015, in press.

Kieseier BC, Wiendl H. Therapie der Multiplen Sklerose - Aktuelles therapeutisches Vorgehen und Perspektiven. Uni-med Verlag, Bremen, 2015, in press.

Kieseier BC, Wiendl H. Corroborating the orale therapeutic pathway in multiple sclerosis - new evidence for teriflunomide (Editorial) Lancet Neurology 2015, in press.

Kieseier BC, Arnold DL, Balcer LJ, Boyko AA, Pelletier J, Liu S, Zhu Y, Seddighzadeh A, Hung S, Deykin A, Sheikh SI, Calabresi PA. Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE. Multiple Sclerosis 2015; 21: 1025-1035.

Kieseier BC. Multiple sclerosis - a dynamic field with a need for excellent education.

European Journal of Neurology 2015, Suppl 2: 1-2.

Kieseier BC, Wiendl H. Nrf2 and beyond: deciphering the mode of action of fumarates in the inflamed central nervous system. Acta Neuropathologica 2015; 130: 297-298.

Kim SH, Hyun JW, Jeong IH, Joung A, Yeon JL, Dehmel T, Adams O, Kieseier BC, Kim HJ. Anti-JC virus antibodies in rituximab-treated patients with neuromyelitis optica spectrum disorder. Journal of Neurology 2015; 262: 696-700.

Kleiser R, Nickel N, Seitz RJ, Trenkler J, Wurm G. Brain Tumors: Clinical Applications of Functional Magnetic Resonance Imaging and Diffusion Tensor Imaging. In: Tumors of the Central Nervous System . Springer, Heidelberg, Chapter 20, 2015, in press.

Klepp A, Niccolai V, Buccino G, Schnitzler A, Biermann-Ruben K. Language-motor interference reflected in MEG beta oscillations. Neuroimage 2015;109: 438-448.

Knuesting J, Riondet C, Maria C, Kruse I, Bécuwe N, König N, Berndt C, Tourrette S, Guilleminot-Montoya J, Herrero E, Gaymard F, Balk J, Belli G, Scheibe R, Reichheld JP, Rouhier N, Rey P. Arabidopsis glutaredoxin S17 and its partner, the nuclear factor Y subunit C11/negative cofactor 2a, contribute to maintenance of the shoot apical meristem under long-day photoperiod. Plant Physiology 2015; 167: 1643-1658.

Kocur M, Schneider R, Pulm AK, Bauer J, Kropp S, Gliem M, Ingwersen J, Goebels N, Alferink J, Prozorovski T, Aktas O, Scheu S. IFNb secreted by microglia mediates clearance of myelin debris in CNS autoimmunity. Acta Neuropathologica Communications 2015; 3: 20.

Kremer D, Küry P, Dutta R. Promoting remyelination in multiple sclerosis: Current drugs and future prospects. Multiple Sclerosis Journal 2015, in press.

Kremer D, Förster M, Schichel T, Göttle P, Hartung HP, Perron H, Küry P. The neutralizing antibody GNbAC1 abrogates HERV-W envelope protein-mediated oligodendroglial maturation blockade. Multiple Sclerosis Journal 2015; 21: 1200-1203.

Kremer D, Hartung H-P, Stangel M, Küry P. Neue Therapiestrategien zur Myelinreparatur bei der Multiplen Sklerose. Nervenarzt 2015; 86: 934-946.

Krumbholz M, Hofstadt van Oy U, Angstwurm K, Kleiter I, Jarius S, Paul F, Aktas O, Buchholz G, Kern P, Straube A, Kümpfel T. Very late-onset neuromyelitis optica spectrum disorder beyond the age of 75. Journal of Neurology 2015, in press.

Kuhle J, Disanto G, Dobson R, Adiutori R, Bianchi L, Topping J, Bestwick J, Meier UC, Marta M, Costa GD, Runia T, Evdoshenko E, Lazareva N, Thouvenot E, Iaffaldano P, Direnzo V, Khademi M, Piehl F, Comabella M, Sombekke M, Killestein J, Hegen H, Rauch S, D'Alfonso S, Alvarez-Cermeño J, Kleinová P, Horáková D, Roesler R, Lauda F, Llufriu S, Avsar T, Uygunoglu U, Altintas A, Saip S, Menge T, Rajda C, Bergamaschi R, Moll N, Khalil M, Marignier R, Dujmovic I, Larsson H, Malmestrom C, Scarpini E, Fenoglio C, Wergeland S, Laroni A, Annibali V, Romano S, Martínez A, Carra A, Salvetti M, Uccelli A, Torkildsen Ø, Myhr K, Galimberti D, Rejdak K, Lycke J, Frederiksen J, Drulovic J, Confavreux C, Brassat D, Enzinger C, Fuchs S, Bosca I, Pelletier J, Picard C, Colombo E, Franciotta D, Derfuss T, Lindberg R, Yaldizli Ö, Vécsei L, Kieseier B, Hartung HP, Villoslada P, Siva A, Saiz A, Tumani H, Havrdová E, Villar L, Leone M, Barizzone N, Deisenhammer F, Teunissen C, Montalban X, Tintoré M, Olsson T, Trojano M, Lehmann S, Castelnovo G, Lapin S, Hintzen R, Kappos L, Furlan R, Martinelli V, Comi G, Ramagopalan S, Giovannoni G. Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. Multiple Sclerosis 2015; 21: 1013-1024.

Kuhle J, Hardmeier M, Disanto G, Gugleta K, Ecsedi M, Lienert C, Amato MP, Baum K, Buttmann M, Bayas A, Brassat D, Brochet B, Confavreux C, Edan G, Färkkilä M, Fredrikson S, Frontoni M, D'Hooghe M, Hutchinson M, De Keyser J, Kieseier BC, Kümpfel T, Rio J, Polman C, Roullet E, Stolz C, Vass K, Wandinger KP, Kappos L; European Long-term Follow-up Study Group in Interferon β-1b in Secondary-progressive Multiple Sclerosis. A 10-year follow-up of the European multicenter trial of interferon β-1b in secondary-progressive multiple sclerosis. Multiple Sclerosis 2015, in press.

Lang N, Esser W, Evers S, Kellinghaus C, Nguento A, Schlegel U, Gaida B, Gburek-Augustat J, Altenmüller DM, Burghaus L, Hoffmann F, Fiedler B, Bast T, Rehfeld T, Happe S, Seitz RJ, Boor R, Stephani U. Intravenous levetiracetam in clinical practice--Results from an independent registry. Seizure 2015; 29: 109-113.

Lange J, Pavlidou A, Schnitzler A. Lateralized modulation of beta-band power in sensorimotor areas during action observation. Frontiers in Integrative Neuroscience 2015; 9: 43

Lauenstein AS, Stettner M, Kieseier BC, Lensch E. Treating neuromyelitis optica with the interleukin-6 receptor antagonist tocilizumab. BMJ Case Report 2015, in press.

Leal A, Huehne K, Bauer F, Sticht H, Berger P, Suter U, Morera B, Del Valle G, Lupski JR, Ekici A, Pasutto F, Endele S, Barrantes R, Berghoff C, Berghoff M, Neundörfer B, Heuss D, Dorn T, Young P, Santolin L, Uhlmann T, Meisterernst M, Sereda M, Zu Horste GM, Nave KA, Reis A, Rautenstrauss B. Identification of the variant Ala335Val of MED25 as responsible for CMT2B2: molecular data, functional studies of the SH3 recognition motif and correlation between wild-type MED25 and PMP22 RNA levels in CMT1A animal models. Neurogenetics2015, in press.

Leussink VI, Warnke C, Tackenberg B, Wiendl H, Kieseier BC. Eine neue Therapieoption zur Behandlung der schubförmigen multiplen Sklerose. Nervenarzt 2015; 86: 483-490.

Lindenberg R, Seitz RJ. Impact of white matter damage after stroke. In: Neuroimaging / Book 1 . Intech Publisher, 2015, in press.

Linke S, Görtz P, Retzlik J, Baader SL, Gieselmann J, Siebler M, Junghans U, Kappler J. Aldolase C/ZebrinII is released to the extracellular space after cell death, interacts with glycosaminoglycans of the extracellular matrix and inhibits the network activity of cortical neurons. Stroke 2015, in press.

Mäurer M, Ortler S, Baier M, Meergans M, Scherer P, Hofmann WE, Tracik F. Randomised multicentre trial on safety and efficacy of rivastigmine in cognitively impaired multiple sclerosis patients. Multiple Sclerosis Journal 2015, in press.

Moldovan AS, Groiss SJ, Elben S, Südmeyer M, Schnitzler A, Wojtecki L. The treatment of Parkinson´s disease with deep brain stimulation: current issues. Neural Regeneration Research 2015; 10: 1018-1022.

Nessler S, Hemmer B. Multiple Sklerose und andere demyelinisierende Erkrankungen. In: Klockgether T, Dodel R (eds.) Kurzlehrbuch Neurologie 2015, in press.

New AB, Robin DA, Parkinson AL, Eickhoff CR, Reetz K, Hoffstaedter F, Mathys C, Südmeyer M, Grefkes C, Larson CR, Ramig LO, Fox PT, Eickhoff SB. The intrinsic resting state voice network in Parkinson's disease. Human Brain Mapping 2015; 36: 1951-1962.

Niccolai V, van Dijk H, Franzkowiak S, Finis J, Südmeyer M, Jonas M, Thomalla G, Siebner HR, Müller-Vahl K, Münchau A, Schnitzler A, Biermann-Ruben K. Increased beta rhythm as an indicator of inhibitory mechanisms in Tourette syndrome. Movement Disorders 2015, in press.

Oeltzschner G, Butz M, Baumgarten TJ, Hoogenboom N, Wittsack HJ, Schnitzler A. Low visual cortex GABA levels in hepatic encephalopathy: links to blood ammonia, critical flicker frequency, and brain osmolytes. Metabolic Brain Dis ease 2015, in press.

Prozorovski T, Schneider R, Berndt C, Hartung HP, Aktas O. Redox-regulated fate of neural stem progenitor cells. Biochimica et Biophysica Acta 2015; 1543-1554.

Quasthoff K, Ferrea S, Fleischer W, Theiss S, Schnitzler A, Dihné M, Walter J. Freshly frozen E18 rat cortical cells can generate functional neural networks after standard cryopreservation and thawing procedures. Cytotechnology 2015; 67: 419-426.

Ringelstein M, Ayzenberg I, Harmel J, Lauenstein AS, Lensch E, Stögbauer F, Hellwig K, Ellrichmann G, Stettner M, Chan A, Hartung HP, Kieseier B, Gold R, Aktas O, Kleiter I. Long-term therapy with interleukin 6 receptor blockade in highly active neuromyelitis optica spectrum disorder. JAMA Neurology 2015; 72: 756-763.

Ringelstein M, Albrecht P, Kleffner I, Bühn B, Harmel J, Müller AK, Finis D, Guthoff R, Bergholz R, Duning T, Krämer M, Paul F, Brandt A, Oberwahrenbrock T, Mikolajczak J, Wildemann B, Jarius S, Hartung HP, Aktas O, Dörr J. Retinal pathology in Susac syndrome detected by spectral-domain optical coherence tomography. Neurology 2015; 85: 610-618.

Rivera FJ, Kraus J, Steffenhagen C, Küry P, Weidner N, Aigner L. Remyelination in multiple sclerosis: The therapeutic potential of neural and mesenchymal stem/progenitor cells.Current Signal Transduction Therapy 2015, in press.

Schippling S, Balk LJ, Costello F, Albrecht P, Balcer L, Calabresi P, Frederiksen J, Frohman E, Green A, Klistorner A, Outteryck O, Paul F, Plant G, Traber G, Vermersch P, Villoslada P, Wolf S, Petzold A. Quality control for retinal OCT in multiple sclerosis: validation of the OSCAR-IB criteria. Multiple Sclerosis 2015; 21: 163-170.

Schira J, Falkenberg H, Hendricks M, Waldera-Lupa DM, Kögler G, Meyer HE. Müller HW, Stühler K. Characterization of regenerative phenotype of unrestricted somatic stem cells from human umbilical cord blood by functional secretome analysis. Molecular & Cellular Proteomics 2015, in press.

Schröder K, Finis D, Harmel J, Ringelstein M, Hartung HP, Geerling G, Aktas O, Guthoff R. Acetazolamide therapy in a case of fingolimod-associated macular edema: early benefits and long-term limitations. Multiple Sclerosis and Related Disorders 2015; 4: 406-408.

Seitz RJ, Meisel S, Moll M, Wittsack HJ, Junghans U, Siebler M. Impact of the MRI "Perfusion-Diffusion Mismatch" for thrombolysis in stroke. Neurology 2015, in press.

Singer OC, Berkefeld J, Nolte CH, Bohner G, Haring HP, Trenkler J, Gröschel K, Müller-Forell W, Niederkorn K, Deutschmann H, Neumann-Haefelin T, Hohmann C, Bussmeyer M, Mpotsaris A, Stoll A, Bormann A, Brenck J, Schlamann MU, Jander S, Turowski B, Petzold GC, Urbach H, Liebeskind DS; ENDOSTROKE Study Group. Mechanical recanalization in basilar artery occlusion: the ENDOSTROKE study. Annals of Neurology 2015; 77: 415-424.

Stangel M, Penner IK, Kallmann BA, Lukas C, Kieseier BC. Towards the implementation of n"no evidence of disease activity" in multiple sclerosis treatment: the multiple sclerosis decision model. Therapeutic Advances in Neurological Disorders 2015; 8: 3-13.

Stettner M, Albrecht P, Derksen A, Hartmann C, Turowski B, Neuen-Jacob E, Hartung HP, Kieseier B, Arendt G. Clinical improvement precedes lesion size regression in a severe case of acute disseminated encephalomyelitis. BMJ Case Reports 2015, in press.

Stettner M, Steinberger D, Hartmann CJ, Pabst T, Konta L, Hartung HP, Kieseier B. Isoniazid-induced polyneuropathy in a tuberculosis patient - implication for individual risk stratification with genotyping? Brain and Behavior 2015; 5: e00326.

Stöckel A, Paassen B, Dickfelder R, Göpfert JP, Brazda N, Müller HW, Cimiano P, Hartung M, Klinger R. SCIE: information extraction for spinal cord injury preclinical experiments - a webservice and open source toolkit. bioRxiv , 2015, in press.

Tzekova N, Heinen A, Bunk S, Hermann C, HartungHP, Reipert B, Küry P. Immunoglobulins stimulate cultured Schwann cell maturation and promote their potential to induce axonal outgrowth. Journal of Neuroinflammation 2015; 12: 107.

Vogel F, Hemmer B. Liquorzirkulationsstörungen. In: Klockgether T, Dodel R (eds.)Kurzlehrbuch Neurologie . 2015, in press.

Vogelaar CF, König B, Krafft S, Estrada V, Brazda N, Ziegler B, Faissner A, Müller HW. Pharmacological suppression of CNS scarring by Deferoxamine reduces lesion volume and increases regeneration in an in vitro model for astroglial-fibrotic scarring and in rat spinal cord injury in ivo. PLoS ONE 10: e0134371.

Wang X, Krebbers J, Charalambous P, Machado V, Schober A, Bosse F, Müller HW, Unsicker K. Growth/differentiation factor-15 and its role in peripheral nervous system lesion and regeneration. Cell and Tissue Research 2015; 362: 267.

Warnke C, Olsson T, Hartung HP. PML - the dark side of immunotherapy in multiple sclerosis.Trends in Pharmacological Sciences 2015, in press.

Warnke C, Stettner M, Dehmel T, Mausberg AK, Hartung HP, Hermsen D, Tumani H, Lehmensiek V, Adams O, Kieseier BC. Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF. Multiple Sclerosis Journal 2015; 21: 1036-1044.

Wiendl H, Kieseier BC. Fragen und Antworten zur Neuroimmunologie. Verlag Hans Huber, Bern, 2015, in press.

Wiendl H, Elger C, Förstl H, Hartung HP, Oertel W, Reichmann H, Schwab S. Gaps between aims and achievements in therapeutic modification of neuronal damage ("neuroprotection").Neurotherapeutics 2015; 12: 449-454.

Winkelmann A, Lobermann M, Reisinger EC, Hartung HP, Zettl UK. Disease modifying therapies and infectious risks in multiple sclerosis. Nature Reviews Neurology 2015, in press

Winkelmann A, Lobermann M, Reisinger EC, Hartung HP, Zettl UK. Immuntherapien und infektiologische Probleme bei Multipler Sklerose: Selbst injizierbare und orale Immuntherapeutika. Nervenarzt 2015; 86: 960-970.

Winkelmann A, Lobermann M, Reisinger EC, Hartung HP, Zettl UK. Infektiologische Risiken in der Multiple-Sklerose-Therapie durch infundierbare Immuntherapeutika. Nervenarzt 2015; 86: 971-977.

Wojtecki L, Schnitzler A. Movement disorders. In: Azari N, et al. (eds.) Encyclopedia of Sciences and Religions . Thieme, 2015, in press.

Wojtecki L, Groiss SJ, Ferrea S, Elben S, Hartmann CJ, Dunnett S, Rosser A, Saft C, Südmeyer M, Ohmann C, Schnitzler A, Vesper J. A prospective pilot trial for pallidal deep brain stimulation in Huntington´s disease. Frontiers in Neurology 2015; 6: 177.

Ziemssen T, de Stefano N, Sormani MP, van Wijmeersch BV, Wiendl H, Kieseier BC. Optimizing therapy early in multiple sclerosis: An evidence-based view. Multiple Sclerosis and Related Disorders 2015; 4: 460-469.

MediathekInformation und Wissen
LageplanSo finden Sie uns